Lonza Group company profile
Company profile
Lonza Group has 20,141 employees and is headquartered in Basel, Switzerland.
Contract development and manufacturing for pharma and biotech companies forms the core of Lonza Group AG, which serves clients in Europe, North and Central America, Latin America, Asia, Australia and New Zealand. Its Integrated Biologics unit covers biologics services from clinical development through drug substance and drug product manufacturing, while Advanced Synthesis makes antibody-drug conjugates, related bioconjugates and potent active ingredients. The Specialized Modalities unit spans cell and gene, microbial, bioscience and mRNA technologies.
In the fiscal year ended December 2025, revenue reached CHF 6.5 billion, up 19.2% from the year before, while the company posted a net loss of CHF 275 million. It employed 20,141 people. Founded as a company incorporated in 1897, it is headquartered in Basel, Switzerland.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Switzerland
- Headquarters
- Muenchensteinerstrasse 38, 4002, Basel
- Employees
- 20,141
- Chief executive
- Wolfgang Wienand
- Founded
- 1897
- Fiscal year
- January - December
- Listing
- LONN · SIX
- Indices
- SMI
- Currency
- CHF
- ISIN
- CH0013841017
- Website
- lonza.com
Lonza Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Lonza GroupLONN | Switzerland | $55.11B | 20,141 | 23.5% | 43.9 |
| Eurofins ScientificERF | France | $16.53B | 65,000 | 14.1% | 30.5 |
| bioMérieuxBIM | France | $11.7B | 14,562 | 16.0% | 23.2 |
| QiagenQIA | Germany | $10.3B | 5,400 | 26.7% | 27.3 |
| DiaSorinDIA | Italy | $4.56B | 3,212 | 22.3% | 31.0 |
| DiagnostykaDIA | Poland | $1.29B | 8,645 | 14.9% | 20.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
